1
|
Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23:2147-52. [PMID: 19626046 DOI: 10.1038/leu.2009.147] [Citation(s) in RCA: 280] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
We present a pooled update of two large, multicenter MM-009 and MM-010 placebo-controlled randomized phase III trials that included 704 patients and assessed lenalidomide plus dexamethasone versus dexamethasone plus placebo in patients with relapsed/refractory multiple myeloma (MM). Patients in both studies were randomized to receive 25 mg daily oral lenalidomide or identical placebo, plus 40 mg oral dexamethasone. In this pooled analysis, using data up to unblinding (June 2005 for MM-009 and August 2005 for MM-010), treatment with lenalidomide plus dexamethasone significantly improved overall response (60.6 vs 21.9%, P<0.001), complete response rate (15.0 vs 2.0%, P<0.001), time to progression (median of 13.4 vs 4.6 months, P<0.001) and duration of response (median of 15.8 months vs 7 months, P<0.001) compared with dexamethasone-placebo. At a median follow-up of 48 months for surviving patients, using data up to July 2008, a significant benefit in overall survival (median of 38.0 vs 31.6 months, P=0.045) was retained despite 47.6% of patients who were randomized to dexamethasone-placebo receiving lenalidomide-based treatment after disease progression or study unblinding. Low beta(2)-microglobulin and low bone marrow plasmacytosis were associated with longer survival. In conclusion, these data confirm the significant response and survival benefit with lenalidomide and dexamethasone.
Collapse
Affiliation(s)
- M A Dimopoulos
- Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Zeldis JB, Heller C, Seidel G, Yuldasheva N, Stirling D, Shutack Y, Libutti SK. A randomized phase II trial comparing two doses of lenalidomide for the treatment of stage IV ocular melanoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20012 Background: Ocular melanoma is the most common primary intraocular malignancy in adults with an incidence of 4.3 new cases per million. Approximately 50% of patients will develop metastases and the mean survival of those with liver metastases is 8–10 months. There are no effective systemic therapies. Pre-clinical studies of the antiangiogenic and immunomodulatory agent, lenalidomide, have shown promise in animal models of human ocular melanoma. We therefore conducted a phase II trial comparing two doses of oral lenalidomide. Methods: Patients with stage IV ocular melanoma, who met eligibility criteria and demonstrated disease progression, were enrolled on an IRB approved prospective random assignment trial comparing 5 mg and 25 mg of lenalidomide administered once a day orally for 21 days with a 7 day recovery (one cycle). Lesions were measured at baseline and every 3 months and scored for response by RECIST criteria. Patients who completed 3 cycles were eligible for response evaluation. Patients with responding lesions or with stable disease could continue receiving the agent. Toxicity was assessed using the NCI Common Toxicity Criteria. Results: Seventeen patients (13 female, 4 male; mean age 53) met eligibility criteria and were randomized to 5 mg (9 patients) or 25 mg (8 patients) of lenalidomide. The agent was well tolerated at both doses with only three grade 3 toxicities (two decreased ANC and one rash/puritis) requiring dose adjustments. Sixteen patients were eligible for response assessments. Nine patients had progressive disease by RECIST criteria following 3 cycles of therapy. Seven patients (44%) had stable disease for a mean of 7 months (range 6–12 months). There were no RECIST defined responders. There were no differences between the two dose groups with respect to toxicity or disease stabilization. Conclusions: Lenalidomide is well tolerated at doses of 5 mg and 25 mg orally for a 21 day cycle by patients with stage IV ocular melanoma. While no responses were seen, disease stabilization for a mean of 7 months was seen in 44% of patients. This effect was consistent with the pre-clinical animal data. Based on these results, further development of lenalidomide in combination with other agents should be considered for the treatment of metastatic ocular melanoma. [Table: see text]
Collapse
Affiliation(s)
- J. B. Zeldis
- Celgene Corporation, Summit, NJ; National Cancer Institute, Bethesda, MD
| | - C. Heller
- Celgene Corporation, Summit, NJ; National Cancer Institute, Bethesda, MD
| | - G. Seidel
- Celgene Corporation, Summit, NJ; National Cancer Institute, Bethesda, MD
| | - N. Yuldasheva
- Celgene Corporation, Summit, NJ; National Cancer Institute, Bethesda, MD
| | - D. Stirling
- Celgene Corporation, Summit, NJ; National Cancer Institute, Bethesda, MD
| | - Y. Shutack
- Celgene Corporation, Summit, NJ; National Cancer Institute, Bethesda, MD
| | - S. K. Libutti
- Celgene Corporation, Summit, NJ; National Cancer Institute, Bethesda, MD
| |
Collapse
|
3
|
Habermann TM, Witzig TE, Lossos IS, Vose JM, Wiernik PH, Weiss L, Ervin-Haynes A, Pietronigro D, Zeldis JB, Czuczman M. Safety of lenalidomide monotherapy in patients with relapsed or refractory aggressive non-Hodgkin’s lymphom. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Hussein MA, Richardson PG, Jagannath S, Singhal S, Bensinger W, Knight R, Zeldis JB, Yu Z, Olesnyckyj M, Anderson KC. Final analysis of MM-014: Single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Witzig TE, Vose JM, Justice G, Kaplan HG, Reeder CB, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Wiernik PH. Lenalidomide oral monotherapy in relapsed/refractory small lymphocytic non-Hodgkin’s lymphoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8573] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Jagannath S, Richardson PG, Zeldenrust S, Alsina M, Wride K, Zeldis JB, Knight R, Olesnyckyj M, Anderson KC. Long-term responses observed with lenalidomide therapy for patients with relapsed or refractory multiple myeloma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8525] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Czuczman MS, Reeder CB, Polikoff J, Chowhan NM, Esseessee I, Greenberg R, Ervin-Haynes A, Pietronigro D, Zeldis JB, Witzig TE. International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8509] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008; 24:1529-38. [PMID: 18419879 DOI: 10.1185/030079908x301866] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE To evaluate the clinical and biological activity of apremilast in patients with severe plaque-type psoriasis. RESEARCH DESIGN AND METHODS Apremilast, a phosphodiesterase-4 inhibitor, inhibits in vitro activity of multiple inflammatory factors implicated in the pathogenesis of psoriasis. Patients received 20 mg apremilast orally for 29 days. Immunohistological analysis was conducted on lesional-skin biopsies for psoriasis-associated inflammatory markers. Lipopolysaccharide-stimulated tumor necrosis factor-alpha levels were evaluated in blood. Psoriasis Area and Severity Index (PASI), static Physician's Global Assessment, and Body Surface Area were used to monitor disease severity. RESULTS There were 19 patients enrolled in this study, of whom 17 completed the study. Epidermal thickness was reduced by a mean of 20.5% from baseline to day 29. Among the responders, T cells were reduced by 28.8% and 42.6% in the dermis and epidermis, respectively. Similarly, CD11c cells were reduced by 18.5% and 40.2% in the dermis and epidermis, respectively. Fourteen of the 19 (73.7%) patients demonstrated an improvement in their PASI scores. LIMITATIONS This was a small, single-arm, open-label pilot study; therefore there was neither a placebo nor a comparison group. CONCLUSION Apremilast demonstrated biological activity and improved psoriasis clinical efficacy scores in patients with severe plaque-type psoriasis. The majority of adverse events were mild in nature. Two adverse events (fatigue and dizziness) were judged by the investigator to be moderate and related to apremilast. In addition, there were no clinically-relevant abnormal laboratory test results in subjects treated with apremilast for 29 days.
Collapse
Affiliation(s)
- A B Gottlieb
- Department of Dermatology, Tufts University, Boston, MA 02111-1533, USA.
| | | | | | | | | | | | | |
Collapse
|
9
|
Mansfield JC, Parkes M, Hawthorne AB, Forbes A, Probert CSJ, Perowne RC, Cooper A, Zeldis JB, Manning DC, Hawkey CJ. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Aliment Pharmacol Ther 2007; 26:421-30. [PMID: 17635377 DOI: 10.1111/j.1365-2036.2007.03385.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease. AIM To evaluate the efficacy and safety of lenalidomide in subjects with moderately severe active Crohn's disease. METHODS In a multicentre, double-blind, placebo-controlled parallel group study 89 subjects were randomized to lenalidomide 25 mg daily, 5 mg daily or placebo. Subjects were treated for 12 weeks. The primary end point was a 70-point reduction in Crohn's Disease Activity Index. RESULTS The overall clinical response rate was not significantly different between the three groups: lenalidomide 25 mg 26%, lenalidomide 5 mg 48% and placebo 39%. Lenalidomide was generally well tolerated with only one serious adverse event, a deep vein thrombosis, being attributed to treatment. CONCLUSION Lenalidomide, an oral agent with antitumour necrosis factor-alpha properties, was not effective in active Crohn's disease in contrast to reports of benefit from thalidomide. The reasons for this lack of efficacy are speculative, other physiological activities may offset its action on inflammatory cytokines, or its antitumour necrosis factor-alpha action without apoptosis may be insufficient for activity in Crohn's disease.
Collapse
Affiliation(s)
- J C Mansfield
- Department of Gastroenterology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Palumbo A, Rus C, Zeldis JB, Rodeghiero F, Boccadoro M. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 2006; 4:1842-5. [PMID: 16879233 DOI: 10.1111/j.1538-7836.2006.02059.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
11
|
Rajkumar SV, Hussein M, Catalano J, Jedrzejcak W, Sirkovich S, Olesnyckyj M, Yu Z, Knight R, Zeldis JB, Blade J. A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7517] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7517 Background: Thalidomide plus dexamethasone (Thal/Dex) yields superior response rates versus dexamethasone (Dex) but its impact as primary therapy for multiple myeloma (MM) is unknown. Methods: Patients (pts) with previously untreated, symptomatic MM were eligible and were randomized in this double-blind trial to Thal/Dex (Arm A) or placebo plus Dex (Arm B). Pts in Arm A received Thal 50 mg PO daily, escalated to 100 mg on day 15, and to 200 mg from day 1 of cycle 2; Dex 40 mg PO was given on days 1–4, 9–12, and 17–20. Pts in Arm B received placebo instead of Thal, and Dex as in Arm A. Cycles were 28 days long, repeated until progression or undue toxicity. The primary endpoint was time to progression (TTP) defined using EBMT criteria. All analyses were intent to treat. Planned sample size was 218 eligible pts in each arm. Full information for one-sided log rank test with significance level of 0.025 (allowing for 1interim analysis) to have 80% power to detect a 40% improvement in TTP (16.8 mo in Arm A vs. 12 mo in Arm B) would be achieved when 282 pts have progressed. A pre-planned interim analysis of the primary endpoint and safety was performed by an independent Data Monitoring Committee (DMC). P value < 0.0015 at this interim analysis would indicate that Arm A is superior to Arm B based on an alpha-spending function of the O’Brien-Fleming type. The DMC recommended release of results. Results: 470 pts were enrolled: 235 randomized to Thal/Dex and 235 to placebo/Dex. Median follow-up was 25 months. Median age was 65 yrs. TTP was significantly superior with Thal/Dex vs placebo/Dex, median TTP 17.4 months (95% CI: 8.1 months-NE) vs 6.4 months (95% CI: 5.6–7.4 months), respectively, P < 0.000065, crossing the upper boundary for superiority. DVT was higher with Thal/Dex vs placebo/Dex, 15.4% vs 4.3%, respectively. Median survival was not reached in either arm. Conclusions: Thal/Dex is significantly superior to Dex alone as first-line therapy for multiple myeloma. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- S. V. Rajkumar
- Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; Frankston Hospital, Frankston, Australia; Medical Academy of Warsaw, Warsaw, Poland; Kiev Institution of Oncology of the UAMS, Kiev, Ukraine; Celgene Corporation, Summit, NJ; Hospital Clinic, Barcelona, Spain
| | - M. Hussein
- Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; Frankston Hospital, Frankston, Australia; Medical Academy of Warsaw, Warsaw, Poland; Kiev Institution of Oncology of the UAMS, Kiev, Ukraine; Celgene Corporation, Summit, NJ; Hospital Clinic, Barcelona, Spain
| | - J. Catalano
- Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; Frankston Hospital, Frankston, Australia; Medical Academy of Warsaw, Warsaw, Poland; Kiev Institution of Oncology of the UAMS, Kiev, Ukraine; Celgene Corporation, Summit, NJ; Hospital Clinic, Barcelona, Spain
| | - W. Jedrzejcak
- Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; Frankston Hospital, Frankston, Australia; Medical Academy of Warsaw, Warsaw, Poland; Kiev Institution of Oncology of the UAMS, Kiev, Ukraine; Celgene Corporation, Summit, NJ; Hospital Clinic, Barcelona, Spain
| | - S. Sirkovich
- Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; Frankston Hospital, Frankston, Australia; Medical Academy of Warsaw, Warsaw, Poland; Kiev Institution of Oncology of the UAMS, Kiev, Ukraine; Celgene Corporation, Summit, NJ; Hospital Clinic, Barcelona, Spain
| | - M. Olesnyckyj
- Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; Frankston Hospital, Frankston, Australia; Medical Academy of Warsaw, Warsaw, Poland; Kiev Institution of Oncology of the UAMS, Kiev, Ukraine; Celgene Corporation, Summit, NJ; Hospital Clinic, Barcelona, Spain
| | - Z. Yu
- Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; Frankston Hospital, Frankston, Australia; Medical Academy of Warsaw, Warsaw, Poland; Kiev Institution of Oncology of the UAMS, Kiev, Ukraine; Celgene Corporation, Summit, NJ; Hospital Clinic, Barcelona, Spain
| | - R. Knight
- Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; Frankston Hospital, Frankston, Australia; Medical Academy of Warsaw, Warsaw, Poland; Kiev Institution of Oncology of the UAMS, Kiev, Ukraine; Celgene Corporation, Summit, NJ; Hospital Clinic, Barcelona, Spain
| | - J. B. Zeldis
- Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; Frankston Hospital, Frankston, Australia; Medical Academy of Warsaw, Warsaw, Poland; Kiev Institution of Oncology of the UAMS, Kiev, Ukraine; Celgene Corporation, Summit, NJ; Hospital Clinic, Barcelona, Spain
| | - J. Blade
- Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, OH; Frankston Hospital, Frankston, Australia; Medical Academy of Warsaw, Warsaw, Poland; Kiev Institution of Oncology of the UAMS, Kiev, Ukraine; Celgene Corporation, Summit, NJ; Hospital Clinic, Barcelona, Spain
| |
Collapse
|
12
|
Wiernik PH, Lossos IS, Justice G, Zeldis JB, Takeshita K, Pietronigro D, Habermann TM, Witzig TE. Preliminary results from two phase II studies of lenalidomide monotherapy in relapsed/refractory non-Hodgkin’s Lymphoma. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17569] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17569 Background: Lenalidomide is an immunomodulatory drug of the IMiD class that has activity in multiple myeloma, myelodysplastic syndromes and chronic lymphocytic leukemia. We report preliminary results of two Phase II studies assessing the safety and efficacy of lenalidomide monotherapy in subjects with relapsed/refractory indolent or aggressive non-Hodgkin’s lymphoma (NHL). Methods: Subjects with indolent (study NHL-001) or aggressive (study NHL-002) relapsed/refractory NHL following ≥ 1 prior treatment regimen with measurable disease are eligible. Subjects receive 25 mg lenalidomide orally once daily on Days 1–21 every 28 days and continue therapy for 52 weeks as tolerated until disease progression. Response and progression are evaluated using cross sectional imaging by the NCI criteria. Results: 10 subjects (2 indolent (I), 8 aggressive (A)) of a planned 80 (40 in each study) have enrolled thus far. Median age is 66 (45–80) and 7 subjects are female. Indolent histology is follicular center lymphoma grade 1, 2 (n = 2) and aggressive histology diffuse large cell lymphoma (n = 7) and follicular center lymphoma grade 3 (n = 1). Median time from diagnosis to lenalidomide monotherapy is 2.9 years (1.1–10) and median number of prior treatment regimens per subject is 3 (1–6). Median duration of follow-up is 2 months. Of eight subjects (2 I, 6 A) evaluable for response at two months, three demonstrated a decrease in their tumor burden by 72% (I), 68% (A) and 52% (A), two subjects (2 A) exhibited stable disease and three subjects (1 I, 2 A) had disease progression. Six of the ten subjects (2 I, 4 A) demonstrated no Grade 3 or 4 adverse events. Grade 3 or 4 hematological adverse events (neutropenia, thrombocytopenia) occurred in four subjects including one febrile neutropenia and one of these four subjects also exhibited Grade 3 cellulitis. No tumor flare or tumor lysis has been observed to date. Conclusions: Preliminary data of lenalidomide monotherapy in relapsed and refractory NHL are encouraging. [Table: see text]
Collapse
Affiliation(s)
- P. H. Wiernik
- New York Medical College, Bronx, NY; University of MIami, Miami, FL; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; Celgene Corporation, Summit, NJ; Mayo Clinic College of Medicine, Rochester, MN
| | - I. S. Lossos
- New York Medical College, Bronx, NY; University of MIami, Miami, FL; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; Celgene Corporation, Summit, NJ; Mayo Clinic College of Medicine, Rochester, MN
| | - G. Justice
- New York Medical College, Bronx, NY; University of MIami, Miami, FL; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; Celgene Corporation, Summit, NJ; Mayo Clinic College of Medicine, Rochester, MN
| | - J. B. Zeldis
- New York Medical College, Bronx, NY; University of MIami, Miami, FL; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; Celgene Corporation, Summit, NJ; Mayo Clinic College of Medicine, Rochester, MN
| | - K. Takeshita
- New York Medical College, Bronx, NY; University of MIami, Miami, FL; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; Celgene Corporation, Summit, NJ; Mayo Clinic College of Medicine, Rochester, MN
| | - D. Pietronigro
- New York Medical College, Bronx, NY; University of MIami, Miami, FL; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; Celgene Corporation, Summit, NJ; Mayo Clinic College of Medicine, Rochester, MN
| | - T. M. Habermann
- New York Medical College, Bronx, NY; University of MIami, Miami, FL; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; Celgene Corporation, Summit, NJ; Mayo Clinic College of Medicine, Rochester, MN
| | - T. E. Witzig
- New York Medical College, Bronx, NY; University of MIami, Miami, FL; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; Celgene Corporation, Summit, NJ; Mayo Clinic College of Medicine, Rochester, MN
| |
Collapse
|
13
|
Mileshkin LR, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients (pts) with multiple myeloma (MM) treated with thalidomide (thal)—Patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7618] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7618 Background: Given new treatment options for pts with MM, physicians are faced with the dilemma of how best to sequence these drugs in order to optimize efficacy and toxicity. Peripheral neuropathy frequently limits the duration of treatment (Rx) with thal. In this study we assessed the utility of serial nerve electrophysiological studies (NES) to detect the onset of neuropathy, and assessed the time course of occurrence and possible clinical and Rx-related predictive factors. Methods: 75 pts with relapsed/refractory MM were enrolled in a multi-centre trial of thal. In addition to clinical assessment, pts underwent sensory and motor NES at baseline and every 3 months in order to identify neuropathy. We examined the value of baseline and serial NES for development of neuropathy, with time to development of neuropathy according to clinical or NES criteria compared using Kaplan-Meier analysis. Differences between pt and Rx-related variables were compared using a Mann-Whitney U-test or a Fisher’s exact test. Results: Thirty nine percent had some NES abnormalities at baseline. Pts were treated with thal at a median dose intensity of 373 mg/day and followed for a median of 18 months (range 6–26). Thirty-one of the 75 pts (41%) developed neuropathy during thal Rx, with 11 (15%) ceasing thal due to neuropathy. The actuarial incidence of any neuropathy increased from 38% at 6 months to 73% at 12 months with 81% of responding pts developing this complication. The use of NES did not reliably predict the imminent development of clinical neuropathy requiring cessation of thal. Nor were pt age, gender or type of prior therapy (ie vincristine) predictive. Development of neuropathy was related to duration of thal exposure with a median time of 268 days thal in those who developed neuropathy compared to 89 days in those who did not (p = 0.0001). Cumulative dose or dose intensity received were not predictive. Conclusions: The majority of pts will develop peripheral neuropathy given sufficient length of thal Rx and to minimize the risk of neurotoxicity, therapy should be limited to less than six months. NES monitoring provides no clear benefit over careful clinical evaluation for the development of clinically significant neuropathy. [Table: see text]
Collapse
Affiliation(s)
- L. R. Mileshkin
- Peter MacCallum Cancer Centre, East Melbourne, Australia; Alfred Hospital, Prahran, Australia; Celgene Corporation, Summit, NJ
| | - R. Stark
- Peter MacCallum Cancer Centre, East Melbourne, Australia; Alfred Hospital, Prahran, Australia; Celgene Corporation, Summit, NJ
| | - B. Day
- Peter MacCallum Cancer Centre, East Melbourne, Australia; Alfred Hospital, Prahran, Australia; Celgene Corporation, Summit, NJ
| | - J. F. Seymour
- Peter MacCallum Cancer Centre, East Melbourne, Australia; Alfred Hospital, Prahran, Australia; Celgene Corporation, Summit, NJ
| | - J. B. Zeldis
- Peter MacCallum Cancer Centre, East Melbourne, Australia; Alfred Hospital, Prahran, Australia; Celgene Corporation, Summit, NJ
| | - H. M. Prince
- Peter MacCallum Cancer Centre, East Melbourne, Australia; Alfred Hospital, Prahran, Australia; Celgene Corporation, Summit, NJ
| |
Collapse
|
14
|
Stadtmauer EA, Weber D, Dimopoulos MA, Borrello I, San-Miguel JF, Hellmann A, Marta Olesnyckyj M, Yu Z, Zeldis JB, Knight RD. Lenalidomide (Len) in combination with dexamethasone (Dex) is more effective than Dex alone at first relapse and provides better outcomes when used early rather than as later salvage therapy in relapsed multiple myeloma (MM). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7600] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7600 Background: High-dose Dex remains a standard therapy for relapsed or refractory MM. Lenalidomide is a novel, oral, immunomodulatory drug (IMiD) that has activity against MM with additive effects when combined with Dex. At the interim analysis of MM-009/010, Len/Dex achieved a significant benefit over Dex, providing a longer median TTP, higher response rates, and higher CR rates. Aim: This prospective subgroup analysis was performed to determine the potential benefit of starting Len/Dex at first relapse by analyzing outcomes versus Dex among patients (pts) who had received only 1 versus >1 prior line of therapy. Methods: Pts who had received 1–3 prior treatments and were not refractory to Dex were randomized to either oral lenalidomide (25 mg daily for 3 weeks every 4 weeks) plus Dex (40 mg on Days 1–4, 9–12, 17–20 every 4 weeks for 4 months, then 40 mg on Days 1–4 every cycle thereafter) or placebo plus Dex. The EBMT criteria were used for response. Randomization was stratified at entry by number of prior therapies (1 versus > 1). Results: Of 692 randomized pts, 241 pts (34%) received only 1 prior therapy. Those receiving 2nd-line Len/Dex had a significantly longer median TTP (66 vs. 20 wks) and a higher RR (CR + PR); (63% vs. 26%) versus those receiving 2nd-line Dex. After a median follow-up of 12.1 mos for all pts, 2nd-line Len/Dex provided significantly improved overall survival (OS) (hazard ratio 1.85, P = 0.03) versus 2nd-line Dex. Among the 451 pts who had received > 1 prior line of therapy, the median TTP (44 vs. 20 wks), RR (57% vs. 20%), and OS (hazard ratio 1.50, P = 0.03) were higher with Len/Dex vs. Dex. Response to Len/Dex was superior to that of Dex regardless of the type of prior therapy. Comparing pts who received Len/Dex as 2nd-line versus later salvage therapy, the median TTP was longer and response rates higher in pts treated in second-line. Conclusions: Len/Dex provided higher response rates and improved TTP compared with Dex at first relapse and beyond. TTP and response rates were superior when Len/Dex was administered earlier at first relapse compared with its use as later salvage therapy. These data support the use of Len/Dex for pts as 2nd-line therapy for relapsed MM. [Table: see text]
Collapse
Affiliation(s)
- E. A. Stadtmauer
- Abramson Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; General Alexandras Hospital, Athens, Greece; Johns Hopkins University, Baltimore, MD; Hospital Universitario de Salamanca, Salamanca, Spain; University of Medicine, Gdansk, Poland; Celgene Corporation, Summit, NJ
| | - D. Weber
- Abramson Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; General Alexandras Hospital, Athens, Greece; Johns Hopkins University, Baltimore, MD; Hospital Universitario de Salamanca, Salamanca, Spain; University of Medicine, Gdansk, Poland; Celgene Corporation, Summit, NJ
| | - M. A. Dimopoulos
- Abramson Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; General Alexandras Hospital, Athens, Greece; Johns Hopkins University, Baltimore, MD; Hospital Universitario de Salamanca, Salamanca, Spain; University of Medicine, Gdansk, Poland; Celgene Corporation, Summit, NJ
| | - I. Borrello
- Abramson Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; General Alexandras Hospital, Athens, Greece; Johns Hopkins University, Baltimore, MD; Hospital Universitario de Salamanca, Salamanca, Spain; University of Medicine, Gdansk, Poland; Celgene Corporation, Summit, NJ
| | - J. F. San-Miguel
- Abramson Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; General Alexandras Hospital, Athens, Greece; Johns Hopkins University, Baltimore, MD; Hospital Universitario de Salamanca, Salamanca, Spain; University of Medicine, Gdansk, Poland; Celgene Corporation, Summit, NJ
| | - A. Hellmann
- Abramson Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; General Alexandras Hospital, Athens, Greece; Johns Hopkins University, Baltimore, MD; Hospital Universitario de Salamanca, Salamanca, Spain; University of Medicine, Gdansk, Poland; Celgene Corporation, Summit, NJ
| | - M. Marta Olesnyckyj
- Abramson Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; General Alexandras Hospital, Athens, Greece; Johns Hopkins University, Baltimore, MD; Hospital Universitario de Salamanca, Salamanca, Spain; University of Medicine, Gdansk, Poland; Celgene Corporation, Summit, NJ
| | - Z. Yu
- Abramson Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; General Alexandras Hospital, Athens, Greece; Johns Hopkins University, Baltimore, MD; Hospital Universitario de Salamanca, Salamanca, Spain; University of Medicine, Gdansk, Poland; Celgene Corporation, Summit, NJ
| | - J. B. Zeldis
- Abramson Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; General Alexandras Hospital, Athens, Greece; Johns Hopkins University, Baltimore, MD; Hospital Universitario de Salamanca, Salamanca, Spain; University of Medicine, Gdansk, Poland; Celgene Corporation, Summit, NJ
| | - R. D. Knight
- Abramson Cancer Center, Philadelphia, PA; M. D. Anderson Cancer Center, Houston, TX; General Alexandras Hospital, Athens, Greece; Johns Hopkins University, Baltimore, MD; Hospital Universitario de Salamanca, Salamanca, Spain; University of Medicine, Gdansk, Poland; Celgene Corporation, Summit, NJ
| |
Collapse
|
15
|
Abstract
Thalidomide is effective in the treatment of multiple myeloma. The immunomodulatory drug and thalidomide analogue lenalidomide is currently in late stage clinical development for MDS and multiple myeloma. This minireview highlights the course of initial and ongoing lenalidomide clinical development in oncology with reference to earlier thalidomide studies.
Collapse
Affiliation(s)
- J B Bartlett
- Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USA.
| | | | | | | |
Collapse
|
16
|
Mileshkin LR, Roberts A, Ganju V, Underhill C, Catalano J, Bell R, Lillie K, Milner AD, Zeldis JB, Prince HM. Quality of life (QOL) assessment in patients with relapsed/refractory multiple myeloma (MM) treated with thalidomide (T) plus celecoxib (Cxb). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. R. Mileshkin
- Peter MacCallum Cancer Ctr, East Melbourne, Victoria, Australia; Royal Melbourne Hosp, Melbourne, Australia; Frankston Hosp, Frankston, Victoria, Australia; Border Medcl Oncology, Albury, Victoria, Australia; Monash Medcl Ctr, Clayton, Australia; The Geelong Hosp, Geelong, Victoria, Australia; Celgene Corp, New Jersey, NJ
| | - A. Roberts
- Peter MacCallum Cancer Ctr, East Melbourne, Victoria, Australia; Royal Melbourne Hosp, Melbourne, Australia; Frankston Hosp, Frankston, Victoria, Australia; Border Medcl Oncology, Albury, Victoria, Australia; Monash Medcl Ctr, Clayton, Australia; The Geelong Hosp, Geelong, Victoria, Australia; Celgene Corp, New Jersey, NJ
| | - V. Ganju
- Peter MacCallum Cancer Ctr, East Melbourne, Victoria, Australia; Royal Melbourne Hosp, Melbourne, Australia; Frankston Hosp, Frankston, Victoria, Australia; Border Medcl Oncology, Albury, Victoria, Australia; Monash Medcl Ctr, Clayton, Australia; The Geelong Hosp, Geelong, Victoria, Australia; Celgene Corp, New Jersey, NJ
| | - C. Underhill
- Peter MacCallum Cancer Ctr, East Melbourne, Victoria, Australia; Royal Melbourne Hosp, Melbourne, Australia; Frankston Hosp, Frankston, Victoria, Australia; Border Medcl Oncology, Albury, Victoria, Australia; Monash Medcl Ctr, Clayton, Australia; The Geelong Hosp, Geelong, Victoria, Australia; Celgene Corp, New Jersey, NJ
| | - J. Catalano
- Peter MacCallum Cancer Ctr, East Melbourne, Victoria, Australia; Royal Melbourne Hosp, Melbourne, Australia; Frankston Hosp, Frankston, Victoria, Australia; Border Medcl Oncology, Albury, Victoria, Australia; Monash Medcl Ctr, Clayton, Australia; The Geelong Hosp, Geelong, Victoria, Australia; Celgene Corp, New Jersey, NJ
| | - R. Bell
- Peter MacCallum Cancer Ctr, East Melbourne, Victoria, Australia; Royal Melbourne Hosp, Melbourne, Australia; Frankston Hosp, Frankston, Victoria, Australia; Border Medcl Oncology, Albury, Victoria, Australia; Monash Medcl Ctr, Clayton, Australia; The Geelong Hosp, Geelong, Victoria, Australia; Celgene Corp, New Jersey, NJ
| | - K. Lillie
- Peter MacCallum Cancer Ctr, East Melbourne, Victoria, Australia; Royal Melbourne Hosp, Melbourne, Australia; Frankston Hosp, Frankston, Victoria, Australia; Border Medcl Oncology, Albury, Victoria, Australia; Monash Medcl Ctr, Clayton, Australia; The Geelong Hosp, Geelong, Victoria, Australia; Celgene Corp, New Jersey, NJ
| | - A. D. Milner
- Peter MacCallum Cancer Ctr, East Melbourne, Victoria, Australia; Royal Melbourne Hosp, Melbourne, Australia; Frankston Hosp, Frankston, Victoria, Australia; Border Medcl Oncology, Albury, Victoria, Australia; Monash Medcl Ctr, Clayton, Australia; The Geelong Hosp, Geelong, Victoria, Australia; Celgene Corp, New Jersey, NJ
| | - J. B. Zeldis
- Peter MacCallum Cancer Ctr, East Melbourne, Victoria, Australia; Royal Melbourne Hosp, Melbourne, Australia; Frankston Hosp, Frankston, Victoria, Australia; Border Medcl Oncology, Albury, Victoria, Australia; Monash Medcl Ctr, Clayton, Australia; The Geelong Hosp, Geelong, Victoria, Australia; Celgene Corp, New Jersey, NJ
| | - H. M. Prince
- Peter MacCallum Cancer Ctr, East Melbourne, Victoria, Australia; Royal Melbourne Hosp, Melbourne, Australia; Frankston Hosp, Frankston, Victoria, Australia; Border Medcl Oncology, Albury, Victoria, Australia; Monash Medcl Ctr, Clayton, Australia; The Geelong Hosp, Geelong, Victoria, Australia; Celgene Corp, New Jersey, NJ
| |
Collapse
|
17
|
Miller KC, Czuczman MS, Dimiceli L, McCarthy P, Bernstein ZP, Zeldis JB, Mohr A, Chanan-Khan AA. Antileukemic effects of novel immunomodulatory agent lenalinomide (L) with or without rituximab (R) in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL). Encouraging preliminary results of an ongoing phase II clinical study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6557] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. C. Miller
- Roswell Park Cancer Institute, Buffalo, NY; Celgene Corp, Warren, NJ
| | - M. S. Czuczman
- Roswell Park Cancer Institute, Buffalo, NY; Celgene Corp, Warren, NJ
| | - L. Dimiceli
- Roswell Park Cancer Institute, Buffalo, NY; Celgene Corp, Warren, NJ
| | - P. McCarthy
- Roswell Park Cancer Institute, Buffalo, NY; Celgene Corp, Warren, NJ
| | - Z. P. Bernstein
- Roswell Park Cancer Institute, Buffalo, NY; Celgene Corp, Warren, NJ
| | - J. B. Zeldis
- Roswell Park Cancer Institute, Buffalo, NY; Celgene Corp, Warren, NJ
| | - A. Mohr
- Roswell Park Cancer Institute, Buffalo, NY; Celgene Corp, Warren, NJ
| | - A. A. Chanan-Khan
- Roswell Park Cancer Institute, Buffalo, NY; Celgene Corp, Warren, NJ
| |
Collapse
|
18
|
Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K, Dannenberg AJ. Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2. Clin Cancer Res 2001; 7:3349-55. [PMID: 11705847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
We investigated the effect of thalidomide, a compound with immunomodulatory and antiangiogenic properties, on lipopolysaccharide (LPS)-mediated induction of cyclooxygenase-2 (Cox-2) and prostaglandin (PG) biosynthesis in murine macrophages. Thalidomide caused a dose-dependent inhibition of LPS-mediated induction of PGE(2) synthesis in RAW 264.7 cells. The induction of Cox-2 protein and mRNA by LPS was also suppressed by thalidomide. Based on the results of nuclear run-off assays and transient transfections, treatment with LPS stimulated Cox-2 transcription, an effect that was unaffected by thalidomide. Thalidomide decreased the stability of Cox-2 mRNA. A series of structural analogues of thalidomide also inhibited LPS-mediated induction of Cox-2 and PGE(2) synthesis. Taken together, these data provide new insights into the antineoplastic and anti-inflammatory properties of thalidomide.
Collapse
Affiliation(s)
- J Fujita
- Department of Surgery, New York Presbyterian Hospital and Weill Medical College of Cornell University, New York, NY 10021, USA
| | | | | | | | | |
Collapse
|
19
|
Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117:1278-87. [PMID: 10579968 DOI: 10.1016/s0016-5085(99)70277-5] [Citation(s) in RCA: 217] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND & AIMS Thalidomide decreases production of tumor necrosis factor alpha, a proinflammatory cytokine associated with Crohn's disease (CD). In this study the safety, tolerance, and efficacy of low-dose thalidomide were evaluated for treatment of moderate-to-severe, steroid-dependent CD. METHODS Twelve adult male patients with Crohn's Disease Activity Index (CDAI) scores of > or = 250 and < or = 500 despite > or = 20 mg prednisone/day were enrolled. The first 6 patients received 50 mg thalidomide every night, the next 6 received 100 mg every night. Steroid doses were stable during the first 4 weeks of treatment, then tapered during weeks 5-12. CDAI was used to assess response. RESULTS (1) Disease activity improved consistently in all patients during weeks 1-4: 58% response, 17% remission. (2) Clinical improvement was generally maintained despite steroid taper during weeks 5-12. All patients were able to reduce steroids by >/=50%. Forty-four percent discontinued steroids entirely. In weeks 5-12, 70% of patients responded and 20% achieved remission. (3) Side effects were mild and mostly transient, with the most common being drowsiness, peripheral neuropathy, edema, and dermatitis. CONCLUSIONS Low-dose thalidomide appears to be well tolerated and effective over a 12-week period. Results of this pilot study support the need for controlled multicenter trials of thalidomide for treatment of CD.
Collapse
Affiliation(s)
- E A Vasiliauskas
- Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, and UCLA School of Medicine, Los Angeles, CA 90048, USA
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Abstract
In July 1998, the US Food and Drug Administration approved the marketing of thalidomide for the treatment of cutaneous manifestations of erythema nodosum leprosum. To ensure that fetal exposure to this teratogenic agent does not occur, the manufacturer has instituted a comprehensive program to control prescribing, dispensing, and use of the drug. This program, known as the System for Thalidomide Education and Prescribing Safety (S.T.E.P.S. [Celgene Corporation, Warren, New Jersey]), is based in part on experience gained with other drugs--specifically isotretinoin and clozapine--that offer important clinical benefits but carry the potential for serious harm. To achieve its goal of the lowest possible incidence of drug-associated teratogenicity, the S.T.E.P.S. program uses a three-pronged approach: (1) controlling access to the drug; (2) educating prescribers, pharmacists, and patients; and (3) monitoring compliance. Clinicians who wish to prescribe thalidomide must be registered in the S.T.E.P.S. Prescriber Registry and agree to prescribe the drug in accordance with S.T.E.P.S. patient eligibility criteria and monitoring procedures. Pharmacies must also register and agree to comply with patient identification and monitoring criteria. Finally, patients receive visual aids, including a videotape, written material, and verbal counseling about the benefits and risks of thalidomide therapy, the importance of not becoming pregnant during therapy, and the types of contraception required (including emergency contraception) and their availability. Women of childbearing potential must agree to undergo pregnancy testing before starting therapy and on a regular schedule during therapy. All patients must agree to complete a confidential survey about their compliance with contraception, testing, and drug therapy. The manufacturer is monitoring survey results and outcome data and is prepared to make whatever modifications to the S.T.E.P.S. program are necessary to ensure its effectiveness. In addition to minimizing the potential risk for fetal harm associated with thalidomide therapy, the S.T.E.P.S. program may provide a model for future cases in which a drug offers compelling benefits but poses profound risks unless its distribution is carefully controlled.
Collapse
Affiliation(s)
- J B Zeldis
- Department of Medical Affairs, Celgene Corporation, Warren, New Jersey 07059, USA
| | | | | | | |
Collapse
|
21
|
Abstract
Hepatitis-associated aplastic anemia (HAAA) is an uncommon disorder that usually is not due to hepatitis A or B virus infection. Hepatitis C virus (HCV) seropositivity is infrequently observed in aplastic anemia (AA) patients who have not been extensively transfused. However, HCV seropositivity may not be detected until several weeks or months after viral infection and AA patients may exhibit defective humoral immunity. Therefore, we evaluated sera from AA patients for the presence of HCV viremia using a reverse transcriptase polymerase chain reaction (RT-PCR) based assay and several serologic assays for HCV antibodies. Serum samples from 90 AA patients who presented to the UCLA Medical Center between March 1984 and February 1990 were analyzed. Overall, 17 patients were found to have HCV viremia by RT-PCR assay, of whom 14 had a positive second-generation HCV enzyme immunoassay (EIA-2) and only 6 were EIA-1 reactive. The frequency of HCV viremia increased with the duration of time between diagnosis and sample procurement, and the number of blood products transfused prior to sampling (P = 0.026). No patient who received fewer than 20 U of blood products or who was sampled less than 20 days after diagnosis had a positive HCV RT-PCR result. Of four patients with hepatitis-associated AA (HAAA), one who was sampled 23 days after diagnosis had hepatitis C viremia and a reactive EIA-2 assay. Therefore, the high frequency of HCV viremia in this patient population is most likely due to transfusion with contaminated blood products prior to the introduction of routine blood donor screening for HCV.
Collapse
Affiliation(s)
- R L Paquette
- Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, California 90095-1678, USA
| | | | | | | | | | | |
Collapse
|
22
|
Castell DO, Sigmund C, Patterson D, Lambert R, Hasner D, Clyde C, Zeldis JB. Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group. Am J Gastroenterol 1998; 93:547-52. [PMID: 9576446 DOI: 10.1111/j.1572-0241.1998.163_b.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
OBJECTIVE We evaluated the efficacy and safety of a twice-daily dosage regimen of cisapride 20 mg in relieving the symptoms of mild-moderate gastroesophageal reflux disease (GERD) in patients with moderate intensity heartburn and no history of erosive esophagitis. METHODS After a 2-wk, single-blind, placebo run-in period, 398 patients who continued to experience moderate intensity heartburn were randomized to either placebo (n = 196) or cisapride 20 mg (n = 202) twice daily for 4 wk. RESULTS Compared with placebo, cisapride significantly reduced scores for daytime and nighttime heartburn (p < 0.001), total regurgitation (p < 0.001), eructation (p = 0.04), and early satiety (p = 0.04). Cisapride 20 mg b.i.d. was also superior to placebo in reducing total use of rescue antacid medication (p < 0.001); reducing, in concordance analyses, daytime and nighttime heartburn with antacid usage (p < 0.001); increasing the percentage of heartburn-free days and antacid-free nights (p < 0.5); and increasing the percentage of patients self-rated as having minimal or better symptomatic improvement (p = 0.01). Cisapride 20 mg b.i.d. was well tolerated. The most common adverse event in the cisapride group was diarrhea, reported by 10% of patients, compared with an incidence of 4% in the placebo group. CONCLUSION Cisapride 20 mg b.i.d. was shown to be effective and safe for the short-term treatment of daytime and nighttime heartburn and for other symptoms associated with mild-moderate GERD.
Collapse
Affiliation(s)
- D O Castell
- Allegheny University Hospitals, Philadelphia, Pennsylvania 19146, USA
| | | | | | | | | | | | | |
Collapse
|
23
|
Lim D, Farup C, Lawrence BJ, Sorrell L, Dubois RW, Zeldis JB. Gastrointestinal illness in managed care: healthcare utilization and costs. Am J Manag Care 1997; 3:1859-72. [PMID: 10178475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
Identification of inefficiencies is a first step to improving the quality of gastrointestinal (GI) care at the most reasonable cost. This analysis used administrative data to examine the healthcare utilization and associated costs of the management of GI illnesses in a 2.5 million-member private managed care plan containing many benefit designs. An overall incidence of 10% was found for GI conditions, with a preponderance in adults (patients older than 40 years) and women. The most frequently occurring conditions were abdominal pain, nonulcer peptic diseases, lower GI tract diseases, and other GI tract problems. These conditions, along with gallbladder/biliary tract disease, were also the most costly. Claims submitted for care during GI episodes averaged $17 per member per month. Increasing severity of condition was associated with substantial increases in utilization and costs (except for medication use). For most GI conditions, approximately 40% of charges were for professional services (procedures, tests, and visits) and 40% of charges were for facility admissions. The prescription utilization analysis indicated areas where utilization patterns may not match accepted guidelines, such as the low use of anti-Helicobacter pylori therapy, the possible concomitant use of nonsteroidal anti-inflammatory drugs in patients with upper GI diseases, and the use of narcotics in treating patients with lower GI disease and abdominal pain. Also, there was no clear relationship between medication utilization and disease severity. Thus, this analysis indicated that GI disease is a significant economic burden to managed care, and identified usage patterns that potentially could be modified to improve quality of care.
Collapse
Affiliation(s)
- D Lim
- Value Health Sciences, Santa Monica, CA 90404, USA.
| | | | | | | | | | | |
Collapse
|
24
|
|
25
|
Mendoza EC, Paglieroni TG, Zeldis JB. Decreased phorbol myristate acetate-induced release of tumor necrosis factor-alpha and interleukin-1 beta from peripheral blood monocytes of patients chronically infected with hepatitis C virus. J Infect Dis 1996; 174:842-4. [PMID: 8843226 DOI: 10.1093/infdis/174.4.842] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Hepatitis C virus (HCV) has been detected in peripheral blood mononuclear cells (PBMC) from persons chronically infected with HCV. Reports describe altered monocytic function during HCV infection; however, the immunologic consequences of HCV tropism for human macrophages are not well defined. Thus, the possibility that HCV infection of monocytes may alter patterns of cytokine release was investigated. The in vitro secretion of tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 beta in response to phorbol myristate acetate-stimulated monocytes and PBMC of subjects chronically infected or not infected with HCV was compared. TNF-alpha and IL-1 beta release were suppressed in cells from infected subjects. Although virus-induced immunosuppression is not a major clinical syndrome of HCV infection, the findings support a hypothesis that HCV can induce selective defects in antigen-presenting cells that may enhance the ability of HCV to persist despite the presence of cytotoxic killer cells and antibody directed against HCV.
Collapse
Affiliation(s)
- E C Mendoza
- University of California, Department of Biochemistry and Molecular Biology, Davis, USA
| | | | | |
Collapse
|
26
|
Mack KD, Walzem RL, Lehmann-Bruinsma K, Powell JS, Zeldis JB. Polylysine enhances cationic liposome-mediated transfection of the hepatoblastoma cell line Hep G2. Biotechnol Appl Biochem 1996; 23:217-20. [PMID: 8679107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Plasmid DNA condensed by polylysine enhanced cationic-liposome-mediated transfection of Hep G2 cells. The luciferase expression plasmid pCMVL was complexed with the polycation poly-L-lysine and mixed with liposomes that contained a 1:1 molar ratio of the cationic lipid 1,2-dioleoyloxy-3-trimethyl-ammoniumpropane, with the neutral phospholipid 1,2-di-(cis-9-octadecenoyl)-sn-glycero-3-phosphoethanolamine. Polylysine enhanced cationic-liposome-mediated transfection of the hepatoblastoma cell line Hep G2 9-fold compared with pCMVL complexed alone with liposomes. The ratio of cationic to anionic charge of the polylysine-pCMVL complexes, and the quantity of cationic liposomes, are important determinants for optimal transfection of Hep G2 cells.
Collapse
Affiliation(s)
- K D Mack
- Department of Microbiology, University of California, Davis 95616, USA
| | | | | | | | | |
Collapse
|
27
|
Shabib SM, Tufenkeji H, Zeldis JB. Reply: Diagnosis of viral hepatitis. Ann Saudi Med 1995; 15:545-6. [PMID: 17589006 DOI: 10.5144/0256-4947.1995.545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Affiliation(s)
- S M Shabib
- Pediatric Gastroenterology and Clinical Nutrition, Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia and Clinical Research, Sandoz Research Institute, East Hanover, New Jersey, USA
| | | | | |
Collapse
|
28
|
Nowicki MJ, Welch TR, Ahmad N, Kuramoto IK, Mendoza EC, Zeldis JB, Baroudy BM, Balistreri WF. Absence of hepatitis B and C viruses in pediatric idiopathic membranoproliferative glomerulonephritis. Pediatr Nephrol 1995; 9:16-8. [PMID: 7742214 DOI: 10.1007/bf00858957] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The blood-borne hepatitis viruses, hepatitis B virus (HBV) and hepatitis C virus (HCV), have similar epidemiological features. The association of chronic HBV infection and glomerulonephritis is well established, particularly in children. Recent reports have shown an association between HCV infection and glomerulonephritis in adults. In order to assess the role of these hepatotropic viruses in membranoproliferative glomerulonephritis (MPGN) we screened 34 children with idiopathic MPGN for the presence of HBV and HCV infection using highly sensitive polymerase chain reaction techniques for the detection of HBV DNA and HCV RNA. Also, enzyme-linked immunosorbent assays were used to detect the presence of antibody to hepatitis B surface antigen and antibody to HCV. No evidence of HBV or HCV infection was demonstrated in any of the patients. We conclude that HBV and HCV are not significant causes of idiopathic MPGN in children in the United States.
Collapse
Affiliation(s)
- M J Nowicki
- Division of Pediatric Gastroenterology, Children's Hospital Research Foundation, Cincinnati, Ohio, USA
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Schiff GM, Sherwood JR, Zeldis JB, Krause DS. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health 1995; 16:12-7. [PMID: 7742331 DOI: 10.1016/1054-139x(94)00105-n] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
PURPOSE A prospective, two-armed, open-label, randomized trial was performed to compare the geometric mean titers (GMT), seroprotection (SP) and seroconversion (SC) rates found after administration of two doses of recombinant hepatitis B vaccine. METHODS Recombinant hepatitis B vaccine 10 or 20 micrograms was administered IM at 0, 1, and 6 months in healthy adolescents. RESULTS Volunteers who received either dose of the vaccine had similarly high seroconversion and seroprotection rates at all visits. At Month 8, both doses of the vaccine were highly immunogenic with GMTs of 1989 mIU/mL (10 micrograms dose) and 7672 mIU/mL (20 micrograms dose) and nearly equivalent SP rates (97% and 99% in the 10 and 20 micrograms dose groups, respectively). The geometric mean titers of seroconverters at Months 3, 6 and 8 were significantly greater in the 20 micrograms group as compared to the 10 micrograms group (p < or = 0.003). Both doses were well-tolerated, with injection site pain the most common reported adverse event. Injection site pain was reported significantly (p = 0.004) more by volunteers who received the 20 micrograms dose (10.7%) compared with volunteers who received the 10 micrograms dose (3.8%). CONCLUSION Vaccination with 10 micrograms of recombinant hepatitis B vaccine may provide a clinically effective and economical alternative to the use of the 20 micrograms dose in healthy adolescents.
Collapse
Affiliation(s)
- G M Schiff
- James N. Gamble Institute of Medical Research, University of California, Sacramento, USA
| | | | | | | |
Collapse
|
30
|
Affiliation(s)
- J B Zeldis
- Clinical Research, Sandoz Research Institute, East Hanover, New Jersy, USA, Pediatric Gastroenterology and Clinical Nutrition and Department of Pediatrics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
| | | | | |
Collapse
|
31
|
Affiliation(s)
- H H A-Kader
- Children's Hospital Research Foundation, Cincinnati, OH
| | | | | | | | | | | |
Collapse
|
32
|
Zeldis JB, Jensen P. Hepatitis C virus pathogenicity: the corner pieces of the jigsaw puzzle are found. Gastroenterology 1994; 106:1118-20. [PMID: 8143981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
|
33
|
Hayashi PH, Fernando L, Schuch DR, Koldinger R, Kelly PB, Ingram M, DeFelice R, Marriott SE, Holland PV, Zeldis JB. Seronegative hepatitis C virus liver failure following transplantation of a cadaveric heart. West J Med 1994; 160:368-71. [PMID: 8023494 PMCID: PMC1022438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- P H Hayashi
- Department of Internal Medicine, University of California, Davis, Medical Center, Sacramento
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
The efficiency of cell-specific transfection by receptor-mediated uptake is improved by the use of cationic lipids. Asialoglycoprotein (AP) was conjugated to poly-L-lysine (PL) and complexed with the plasmid pCMVL that contains a luciferase reporter gene. The asialoglycoprotein-poly-L-lysine:pCMVL (AP-PL:pCMVL) complexes then were mixed with the cationic lipid dioctadecylamidoglycylspermine (DOGS). This complex was taken up by the hepatocyte-like cell line, Hep G2, via the asialoglycoprotein receptor. The expression of luciferase in cells transfected with the DOGS/AP-PL: pCMVL complexes were significantly increased compared with AP-PL:pCMVL complexes without DOGS. The ratio of AP-PL to DOGS is an important determinant for both transfection efficiency and for maintaining receptor specificity. Therefore, cationic lipids significantly increased the efficiency of asialoglycoprotein receptor mediated transfection in the hepatoblastoma cell line, Hep G2. The use of cationic lipids with receptor-mediated gene delivery systems could potentially increase transfection efficiency yet maintain cell-target specificity.
Collapse
Affiliation(s)
- K D Mack
- Department of Microbiology, University of California-Davis
| | | | | |
Collapse
|
35
|
Abstract
Over a 15-year period, a white American woman was observed to have progressive hepatitis B that underwent hepatitis Be antigen (HBeAg) positivity to anti-HBe positivity with development of cirrhosis. This patient was found to have a non-sense mutation in the second codon of the pre-C region of the hepatitis B virus genome after her anti-HBe seroconversion but not in her serum when she was HBeAg+. As controls, serial blood specimens were analyzed from 12 other American patients who spontaneously converted from HBeAg to anti-HBe, who underwent an interferon alfa-associated HBeAg to anti-HBe seroconversion, and who did not seroconvert with interferon alfa therapy. No mutations in the pre-C region were observed to arise in these individuals. In conclusion, non-sense mutations that occur in the pre-C region in locations other than the 28th codon can be associated with HBeAg negative progressive liver disease. This report of a non-sense mutation occurring over time is unusual in that it occurred in a white American patient.
Collapse
Affiliation(s)
- J H Lee
- Gastrointestinal Division, University of California Davis Medical Center, Sacramento
| | | | | | | |
Collapse
|
36
|
Schupper H, Hayashi P, Scheffel J, Aceituno S, Paglieroni T, Holland PV, Zeldis JB. Peripheral-blood mononuclear cell responses to recombinant hepatitis C virus antigens in patients with chronic hepatitis C. Hepatology 1993. [PMID: 7693570 DOI: 10.1002/hep.1840180507] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Peripheral blood mononuclear cell proliferative responses in vitro to recombinant yeast or Escherichia coli hepatitis C virus fusion proteins were evaluated in 20 patients with chronic hepatitis C who were reactive for antibody to hepatitis C virus (on enzyme immunoassay, version 2.0, and a four-antigen recombinant immunoblot assay). Twenty age-matched, healthy individuals negative for antibody to hepatitis C virus were used as a control group. Peripheral-blood mononuclear cells from all chronic hepatitis C patients with antibodies to hepatitis C virus antigens c22 and c100-3 proliferated in vitro in response to the corresponding recombinant hepatitis C virus fusion protein. Peripheral-blood mononuclear cells from 75% of patients infected with hepatitis C virus proliferated in response to cytidine monophosphate-keto-3-deoxyoctulosonic acid-core recombinant antigen but there was no proliferative response to cytidine monophosphate-keto-3-deoxyoctulosonic acid-EF (derived from the NS5 region). All hepatitis C virus-infected patients had 33c antibody, but peripheral-blood mononuclear cells from only 9 of 14 (64%) proliferated in vitro in response to 33c. Ninety-five percent of all hepatitis C virus-infected patients had peripheral-blood mononuclear cells that proliferated in response to at least one recombinant hepatitis C virus fusion protein. The numbers and percentages of CD3 T cells, CD19 B cells and natural killer cells from patients with chronic hepatitis C virus infection did not differ from those in the healthy control group. However, the number of non-major histocompatibility complex-restricted cytotoxic T cells (CD3-positive, CD56-positive, CD16-positive) was increased in patients with chronic hepatitis C virus infection (p < 0.05).
Collapse
Affiliation(s)
- H Schupper
- University of California, Davis, Medical Center, Sacramento 95817
| | | | | | | | | | | | | |
Collapse
|
37
|
Hayashi PH, Zeldis JB. Polymerase chain reaction in gastroenterology. J Clin Gastroenterol 1993; 16:329-32. [PMID: 7687260 DOI: 10.1097/00004836-199306000-00014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Polymerase chain reaction (PCR) has had a major impact on molecular biology and is beginning to change our perception of certain disease processes and diagnostic tests. PCR allows the identification and amplification of very rare nucleic acid sequences. This is resulting in our identification of previously elusive infectious agents and of mutations that may affect the course of viral infections or carcinogenesis. PCR can now analyze the expression of genes from single cells or single molecules of nucleic acid from a sample source. Once pitfalls in contamination are overcome and more probes for genes of biological and medical interest become available, PCR technology will become universally employed in the clinical laboratory.
Collapse
Affiliation(s)
- P H Hayashi
- Gastrointestinal Division, University of California Medical Center, Davis, Sacramento
| | | |
Collapse
|
38
|
Aoki SK, Finegold D, Kuramoto IK, Douville C, Richards C, Randell R, Fernando L, Holland PV, Zeldis JB. Significance of antibody to hepatitis B core antigen in blood donors as determined by their serologic response to hepatitis B vaccine. Transfusion 1993; 33:362-7. [PMID: 8488537 DOI: 10.1046/j.1537-2995.1993.33593255593.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Because large numbers of volunteer blood donors may be disqualified for "false-positive" results on tests for antibody to hepatitis B core antigen (anti-HBc), a more specific definition of anti-HBc enzyme immunoassay (EIA)-reactive was evaluated, including only those donor samples that were "strongly" reactive (sample-to-cutoff absorbance ratio, < 0.45). Results using this definition and other anti-HBc test methods were compared to the serologic response (antibody to hepatitis B surface antigen [anti-HBsAg]) to hepatitis B vaccination. Fifty-eight volunteer blood donors who had previously been deferred as donors, because of reactive anti-HBc tests (all other blood screening tests were negative, including those for HBsAg and anti-HBsAg) on two occasions, were vaccinated for hepatitis B. It was assumed that an anamnestic response to vaccine indicated past infection with hepatitis B, while a primary response to vaccine indicated lack of past infection. One (2%) of 43 donors with a historically "weak" anti-HBc (reactive absorbance ratio, > or = 0.45) had an anamnestic response to vaccine, compared to 8 (53%) of 15 with historically "strong" anti-HBc (reactive absorbance ratio, < 0.45) (p < 0.005). Anti-HBc testing using the microparticle EIA method also correlated well with hepatitis B vaccination results. The use of a narrower definition of "reactive" for anti-HBc EIA testing yielded much more specific, but slightly less sensitive, results.
Collapse
Affiliation(s)
- S K Aoki
- Sacramento Medical Foundation Blood Center, California
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
The specificities of four assays for hepatitis C virus (HCV) were compared by using units from volunteer blood donors. Upon Food and Drug Administration licensure of the first immunoassay for anti-HCV, EIA-1, units previously deemed acceptable for transfusion and all subsequent blood donations were screened. EIA-1 repeat-reactive (RR) units were tested for HCV by a second-generation enzyme-linked immunoassay (EIA-2) and by a four-antigen recombinant immunoblot assay (RIBA II) and for HCV RNA by reverse transcriptase polymerase chain reaction. All HCV RNA-positive samples were reactive by both RIBA II and EIA-2. All RIBA II-reactive sera were EIA-2 RR. In EIA-1, 0.45% of the prescreened units and 0.59% of the prospectively screened donors were RR. Of these, 52.5 and 54%, respectively, were EIA-2 RR, 71.4 and 69% of the EIA-2 RR units were reactive on RIBA II, and 93 and 88% of the RIBA II-reactive samples were HCV RNA positive. When the sample/cutoff ratio for EIA-2 was greater than 5, 91% of the samples were RIBA II reactive and 82% of the samples were HCV RNA positive. None of EIA-2 RR units with a sample/cutoff ratio of < 5 was RIBA II reactive or HCV RNA positive. In conclusion, RIBA II and RT PCR results are highly concordant. A sample/cutoff ratio of > 5 in EIA-2 is a good discriminator for the likelihood of a true HCV infection on the basis of RT PCR and RIBA II assays.
Collapse
Affiliation(s)
- H Y Zhang
- Department of Medicine, University of California, Davis Medical Center, Sacramento
| | | | | | | | | | | |
Collapse
|
40
|
Abstract
Hepatitis B virus inhibits the in vitro growth of the human leukemic cell line K562; however, the mechanism of this growth inhibition is not understood. One to 12 days after exposure, viral DNA and RNA were detected in K562 cells by Southern blot and reverse-transcriptase polymerase chain reaction analyses. Virus-containing serum that was heat-inactivated failed to inhibit cell growth and no viral DNA or RNA was detected in these cells. In addition, murine monoclonal antibodies directed to hepatitis B virus surface epitopes neutralized the virus-induced growth inhibition whereas antibodies to hepatitis B virus core epitopes failed to suppress the inhibition. These results indicate that in vitro infection of K562 cells by hepatitis B virus causes inhibition of hematopoietic cell line growth.
Collapse
|
41
|
Gish RG, Warmerdam MT, Zeldis JB, Keeffe EB, Nakazato P, Lim J, Cox K, Kuramoto IK, Fry KE, Yarbough PO. Variation in antibody reactivity to the hepatitis C virus by comparative immunoscreening and enzyme immunoassay. Viral Immunol 1993; 6:49-54. [PMID: 7682814 DOI: 10.1089/vim.1993.6.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
The detection of antibody to the hepatitis C virus C100-3 antigen from the nonstructural region (NS3/NS4) of the viral genome was the first useful marker developed to detect past or potentially active infection with the hepatitis C virus. A systematic epitope survey of the nonstructural region has uncovered other immunogenic antigens. In order to assess the possible diagnostic utility of these antigens, their reactivity against a limited panel of sera from patients with chronic liver disease due to hepatitis C virus and other etiologies was tested. Antibody assays were performed using an immunoblot plaque assay and an enzyme-linked immunosorbent assay (ELISA). In a study of 16 C100-3-reactive individuals, all 16 patients were reactive using the plaque assay for the NS3 3' (409-1-1) and NS3 5' (C33u). In this same group of patients, antibodies by ELISA were reactive to NS3 3' in 12 of 16 patients (75%), NS3 5' in 15 of 16 patients (93%), and a capsid antigen (NC450) in 14 of 16 patients. In a group of five patients who were diagnosed with cryptogenic liver disease (C100-3 negative), 4 of 5 patients were reactive for antibody to all of the above epitopes. In a survey of 23 patients with other forms of chronic liver disease (nonviral liver disease, hepatitis B, alcoholic liver disease, cholestatic liver disease, and autoimmune hepatitis), only 1 of 23 patients was reactive for antibody to the C100-3 and 4 of 23 patients were reactive for antibodies to structural and nonstructural regions of the virus.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- R G Gish
- California Pacific Medical Center, San Francisco
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Bouffard P, Hayashi PH, Acevedo R, Levy N, Zeldis JB. Hepatitis C virus is detected in a monocyte/macrophage subpopulation of peripheral blood mononuclear cells of infected patients. J Infect Dis 1992; 166:1276-80. [PMID: 1385547 DOI: 10.1093/infdis/166.6.1276] [Citation(s) in RCA: 134] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Hepatitis C virus (HCV) is the primary agent of posttransfusion non-A, non-B hepatitis. HCV RNA was detected in peripheral blood mononuclear cells (PBMC) by polymerase chain reaction in 17 of 24 HCV-infected patients with chronic hepatitis with or without cirrhosis. One of 5 patients whose PBMC contained HCV RNA also had negative-stranded HCV RNA in the PBMC. In 3 of 11 patients whose PBMC contained HCV RNA, flow cytometry with a murine monoclonal antibody to HCV core epitope revealed cytoplasmic staining of peripheral blood monocytes. The monocyte surface and the peripheral blood lymphocytes did not stain for HCV core epitopes. No correlation could be made between the presence of HCV RNA or antigen in PBMC and any serologic markers of HCV infection. These results indicate that monocyte uptake of HCV by either phagocytosis or infection may be part of the pathophysiology of this chronic disease.
Collapse
Affiliation(s)
- P Bouffard
- University of California, Medical Center, Davis, Sacramento
| | | | | | | | | |
Collapse
|
43
|
Lee JH, Paglieroni TG, Holland PV, Zeldis JB. Chronic hepatitis B virus infection in an anti-HBc-nonreactive blood donor: variant virus or defective immune response? Hepatology 1992; 16:24-30. [PMID: 1535607 DOI: 10.1002/hep.1840160106] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Viral sequence and host immune response were investigated in an unusual, asymptomatic chronic hepatitis B virus carrier (human leukocyte antigen type A24, Bw61, Bw62, Bw6, DRw11, DRw52, DQw7) who was consistently nonreactive for antibody to HBc and had a normal ALT level over a 5-yr study period. The precore and core region DNA sequences of virus isolated from his serum had seven silent mutations that resulted in no changes in the amino acid sequence of the adr HBsAg subtype. He had no abnormalities in the number of peripheral blood T or B cells and no HBcAg-specific suppressor T cells. His lymphocytes proliferated in vitro in response to phytohemagglutinin, pokeweed mitogen, Staphylococcus aureus and tetanus toxoid but not to recombinant HBcAg. Unlike other HBsAg carriers and hepatitis B virus-immune individuals, his monocytes did not ingest beads coated with HBcAg. Failure to produce antibody to HBc was not due to an hepatitis B virus variant but to a selective immune system defect in this asymptomatic HBsAg carrier.
Collapse
Affiliation(s)
- J H Lee
- University of California-Davis Medical Center, Sacramento 95817
| | | | | | | |
Collapse
|
44
|
Kotwal GJ, Baroudy BM, Kuramoto IK, McDonald FF, Schiff GM, Holland PV, Zeldis JB. Detection of acute hepatitis C virus infection by ELISA using a synthetic peptide comprising a structural epitope. Proc Natl Acad Sci U S A 1992; 89:4486-9. [PMID: 1374903 PMCID: PMC49107 DOI: 10.1073/pnas.89.10.4486] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
An enzyme-linked immunosorbent assay (ELISA) was developed by using a synthetic polypeptide (SP) whose sequence was derived from the structural region of hepatitis C virus (HCV). Results of several coded panels of sera obtained from volunteer blood donors and patients with apparent non-A, non-B hepatitis and/or hepatitis B virus used in this ELISA were compared with those of a commercially available first-generation C-100 ELISA (using nonstructural HCV antigens), an experimental second-generation C-200/C-22 ELISA (using both structural and nonstructural HCV antigens), and recombinant immunoblot assays RIBA-I and RIBA-II. In the majority of cases, the results obtained with the HCV-SP ELISA correlated well with those obtained by RIBA-II and C-200/C-22 ELISA. In contrast, many samples that were repeatedly reactive in the C-100 ELISA results were nonreactive with RIBA and HCV-SP ELISA. In addition, HCV-SP detected HCV-specific antibody that appeared within a month of infection and coincided with the earliest increase in alanine aminotransferase. In summary, we have developed an ELISA based on a structural HCV synthetic polypeptide, HCV-SP, that has high specificity and sensitivity and is capable of detecting specific antibodies in the acute phase of HCV infection.
Collapse
Affiliation(s)
- G J Kotwal
- Division of Molecular Virology, James N. Gamble Institute of Medical Research, Cincinnati, OH 45219
| | | | | | | | | | | | | |
Collapse
|
45
|
Zeldis JB, Jain S, Kuramoto IK, Richards C, Sazama K, Samuels S, Holland PV, Flynn N. Seroepidemiology of viral infections among intravenous drug users in northern California. West J Med 1992; 156:30-5. [PMID: 1310362 PMCID: PMC1003142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Intravenous drug users are frequently exposed to parenterally transmitted viral infections, and these infections can spread to the general population through sexual activity. We investigated the prevalence of serologic markers for human immunodeficiency virus type 1 (HIV-1), human T-cell lymphotropic virus type I/II (HTLV-I/II), hepatitis B virus (HBV), and hepatitis C virus (HCV) in intravenous drug users and their sexual contacts. Of 585 drug users from northern California tested for these serologic markers, 72% were reactive for the antibody to HCV, 71% for the antibody to hepatitis B core antigen, 12% for HTLV-I/II antibodies, and 1% for the HIV-1 antibody. The prevalence of serologic markers for these four viruses correlated with the duration of intravenous drug use, the ethnic group, and the drug of choice. More than 85% of subjects infected with either HCV or HBV were coinfected with the other virus. All persons reactive to HTLV-I/II antibodies had antibodies for either HBV or HCV. Of 81 sexual contacts tested, 17% had evidence of HBV infection while only 6% were reactive for HTLV-I/II antibodies and 4% for the antibody to HCV. None of this group was infected with HIV-1. We conclude that HTLV-I/II and HCV are inefficiently transmitted to sexual contacts while HBV is spread more readily. Programs designed to discourage the sharing of drug paraphernalia, such as needle and syringe exchanges, should decrease the risk of parenterally spread viral infections in intravenous drug users and thus slow the spread of these infections to the general population.
Collapse
Affiliation(s)
- J B Zeldis
- Department of Internal Medicine, University of California, Davis, School of Medicine
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Freeman RB, Sanchez H, Lewis WD, Sherburne B, Dzik WH, Khettry U, Hing S, Zeldis JB, Jenkins RL. Serologic and DNA follow-up data from HBsAg-positive patients treated with orthotopic liver transplantation. Transplantation 1991; 51:793-7. [PMID: 1901676 DOI: 10.1097/00007890-199104000-00011] [Citation(s) in RCA: 31] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Fifteen hepatitis B surface antigen (HBsAg) positive patients treated with orthotopic liver transplantation were studied to determine whether any clinical, serologic, or histologic data were predictive for recurrent hepatitis B infection leading to graft failure. Six patients died early, one due to primary graft nonfunction and the remaining five due to septic complications. There were nine patients surviving longer than two months, eight of whom are alive at a mean follow-up of 556 days. HBsAg and hepatitis B core antibody (anti-HBc) reappeared in the sera of all survivors after a variable transient period of clearance. One patient died 3 months posttransplant of fungal sepsis and was found to have histologic evidence for recurrent hepatitis and positive immunoperoxidase staining postmortem. The remaining eight survivors are home and clinically well, with no histologic evidence of hepatitis. Seven of these eight patients have hepatitis B viral DNA in their sera. We conclude that while there is a high early mortality, usually from sepsis, none of the serologic, histologic, or DNA data analyzed can be used to predict graft loss from recurrent hepatitis. No grafts have been lost due to recurrent hepatitis B in this series, and therefore we believe that HBsAg positive patients should not be excluded from transplantation.
Collapse
Affiliation(s)
- R B Freeman
- Department of Surgery, New England Deaconess Hospital, Boston, Massachusetts
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Hayashi PH, Flynn N, McCurdy SA, Kuramoto IK, Holland PV, Zeldis JB. Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus. J Med Virol 1991; 33:177-80. [PMID: 1715384 DOI: 10.1002/jmv.1890330307] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A study was undertaken to determine the prevalence and risk factors for serological evidence of hepatitis C virus (HCV) infection in patients infected with the human immunodeficiency virus (HIV). Tests for anti-HCV antibody were carried out by enzyme-linked immunoassay (EIA) on 101 HIV-infected patients from two university-based outpatient clinics. Anti-HCV antibody reactive samples were tested by using a recombinant immunoblot assay (RIBA) for HCV antibodies. Fourteen of 101 (13.9%) HIV-infected patients were anti-HCV reactive by EIA. Of these 14, only seven were reactive by RIBA: four were intravenous drug users as a sole risk factor for HIV infection; and the remaining three acquired HIV by blood transfusion, contaminated instrument exposure or IV drug use and sexual contact. Acquisition of HIV by sexual activity alone was not associated with HCV infection. It is concluded that HCV infection is found in approximately 7% of a university HIV clinic population. False-positive anti-HCV antibody serology may lead to overestimation of the prevalence of HCV infection. Female sex and intravenous drug use are significantly associated with HCV infection among HIV-infected individuals.
Collapse
Affiliation(s)
- P H Hayashi
- Division of Internal Medicine, University of California, Davis, Medical Center, Sacramento
| | | | | | | | | | | |
Collapse
|
48
|
Read AE, Donegan E, Lake J, Ferrell L, Galbraith C, Kuramoto IK, Zeldis JB, Ascher NL, Roberts J, Wright TL. Hepatitis C in patients undergoing liver transplantation. Ann Intern Med 1991; 114:282-4. [PMID: 1846278 DOI: 10.7326/0003-4819-114-4-282] [Citation(s) in RCA: 63] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
OBJECTIVE To determine the prevalence of antibodies to hepatitis C virus (anti-HCV) among patients undergoing liver transplantation and the relation between anti-HCV and post-transplant hepatitis. DESIGN Retrospective cohort. PATIENTS Serum samples from 128 patients who underwent liver transplantation. Sixty-six patients who had 6 months of follow-up and for whom both pretransplant and post-transplant serum samples were available were included in a study to asses the relation between anti-HCV and post-transplant hepatitis. MEASUREMENTS Sera were tested for anti-HCV using an enzyme-linked immunosorbent assay (ELISA) and, if positive, two confirmatory tests were done. Patients had a biopsy every week until two specimens showed no abnormal findings. MAIN RESULTS Only patients with chronic non-A, non-B hepatitis (15 of 30; 50%), alcoholic cirrhosis (7 of 19; 37%), and chronic hepatitis B infection (3 of 11; 27%) were anti-HCV positive. No patient with another form of chronic liver disease or with acute liver failure due to non-A, non-B hepatitis was anti-HCV positive. After transplantation, loss of anti-HCV was frequent and acquisition rare. Hepatitis developed in the graft in 17% of patients, but the incidence was similar among anti-HCV negative and anti-HCV-positive patients. CONCLUSIONS Hepatitis C virus is a common cause of chronic liver disease in patients requiring liver transplantation, but anti-HCV is rarely found in patients with acute liver failure. Previous HCV infection, based on detection of anti-HCV, is not an independent risk factor for post-transplant hepatitis.
Collapse
Affiliation(s)
- A E Read
- University of California, San Francisco
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Read AE, Donegan E, Lake J, Ferrell L, Galbraith C, Kuramoto IK, Zeldis JB, Ascher NL, Roberts J, Wright TL. Hepatitis C in liver transplant recipients. Transplant Proc 1991; 23:1504-5. [PMID: 1846471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
HCV infection is commonly found in patients with chronic liver disease undergoing liver transplantation. However, the presence of antibody to HCV does not appear to be associated with the development of hepatitis posttransplant. No other risk factors were identified that appear to predispose patients to development of hepatitis in the posttransplant period, including amount of blood product exposure. The role of immunosuppression in the acquisition and expression of liver disease caused by HCV remains to be determined.
Collapse
Affiliation(s)
- A E Read
- University of California, San Francisco
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
|